Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v3-EN | Version v2-FR | |
|---|---|---|
| Language | English | French |
| Date Updated | 2025-03-17 | 2025-03-17 |
| Drug Identification Number | 02485494 | 02485494 |
| Brand name | BACLOFEN INTRATHECAL | BACLOFEN INTRATHECAL |
| Common or Proper name | Baclofen intrathecal 0.05 mg/mL | Baclofen intrathecal 0.05 mg/mL |
| Company Name | AVIR PHARMA INC. | AVIR PHARMA INC. |
| Ingredients | BACLOFEN | BACLOFEN |
| Strength(s) | 0.05MG | 0.05MG |
| Dosage form(s) | SOLUTION | SOLUTION |
| Route of administration | INTRATHECAL | INTRATHECAL |
| Packaging sizes (GTIN) | (See additional packaging sizes) | (See additional packaging sizes) |
| Additional packaging sizes | 1ml | 1ml |
| ATC code | M03BX | M03BX |
| ATC description | MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS | MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS |
| Reason for discontinuation | Business reasons | Business reasons |
| Anticipated discontinuation date | 2025-03-03 | 2025-03-03 |
| Actual discontinuation date | 2025-03-03 | 2025-03-03 |
| Remaining supply date | 2025-03-03 | 2025-03-03 |
| Discontinuation status | Discontinued | Discontinued |
| Discontinuation decision reversal | no | no |
| Tier 3 Status | No | No |
| Information on remaining supply | ||
| Company comments | This discontinuation only affects the 0.05 mg/mL strength. The other available strengths of baclofen intrathecal (0.5 mg/mL and 2 mg/mL) remain unchanged | This discontinuation only affects the 0.05 mg/mL strength. The other available strengths of baclofen intrathecal (0.5 mg/mL and 2 mg/mL) remain unchanged |
| Health Canada comments |